Genmab A/S ADS (GMAB) is a publicly traded Healthcare sector company. As of October 23, 2026, GMAB trades at $39.99 with a market cap of $24.33B and a P/E ratio of 0.00. GMAB moved +1.10% today. Year to date, GMAB is +25.79%; over the trailing twelve months it is +33.69%. Its 52-week range spans $17.24 to $40.17. Analyst consensus is strong buy with an average price target of $98.52. Rallies surfaces GMAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
10 analysts cover GMAB: 0 strong buy, 9 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $98.52.
| Metric | Value |
|---|---|
| Price | $39.99 |
| Market Cap | $24.33B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.17 |
| 52-Week Low | $17.24 |
| Volume | 4.48M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
10 analysts cover GMAB: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $98.52.